Recombinant Human KCNN3 Protein，GST

KCNN3, also known as the calcium-activated potassium channel KCa3.1, plays a critical role in various physiological processes, including cell proliferation, migration, and apoptosis. This channel is widely expressed in immune cells, endothelial cells, and smooth muscle cells, making it a candidate for therapeutic interventions in conditions such as hypertension, cancer, and autoimmune diseases. The research on KCNN3 recombinant proteins aims to elucidate the structure-function relationship of this channel and its regulatory mechanisms. Understanding these aspects is crucial for the development of selective channel modulators that can either inhibit or enhance channel activity to treat specific disorders. Furthermore, KCNN3's involvement in important signaling pathways, particularly those related to calcium homeostasis and cell activation, underscores the need to investigate its pharmacological potential. Recent studies have focused on characterizing KCNN3 through recombinant technology, allowing for high-yield production and purification of the protein. These recombinant proteins serve as valuable tools for functional assays and structural studies, enabling researchers to explore channel kinetics, ion selectivity, and gating mechanisms. Moreover, the generation of specific KCNN3 inhibitors and activators can provide insights into its biological roles and therapeutic applications, highlighting its significance in both basic and translational research. Thus, the study of KCNN3 and its recombinant forms presents a promising avenue for discovering novel treatments targeting a wide range of diseases linked to calcium signaling and ion channel dysregulation.